Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects

OBJECTIVE: Nintedanib (NIN) is an antifibrotic drug approved to slow the progression of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-related interstitial lung disease (SSc-ILD). NIN can frequently cause gastrointestinal adverse effects. We aimed to investigate the NIN safety profile in...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Battista, Marco, Tavanti, Laura, Pistelli, Francesco, Carrozzi, Laura, Da Rio, Mattia, Rossi, Alessandra, Puccetti, Lorenzo, Tavoni, Antonio, Romei, Chiara, Morganti, Riccardo, Della Rossa, Alessandra, Mosca, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518269/
https://www.ncbi.nlm.nih.gov/pubmed/37535212
http://dx.doi.org/10.1007/s10787-023-01286-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518269/
https://www.ncbi.nlm.nih.gov/pubmed/37535212
http://dx.doi.org/10.1007/s10787-023-01286-x

Ejemplares similares